Caroline Marty

This study shows that silencing fibronectin reduces fibrotic bone marrow niche remodeling and stromal activation in myelofibrosis models.

A first-in-class CAR T-cell therapy targeting mutant calreticulin selectively depletes malignant stem cells in vivo and in fibrotic human organoids.